Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
11.90
-0.15 (-1.24%)
At close: Dec 5, 2025, 4:00 PM EST
11.92
+0.02 (0.17%)
After-hours: Dec 5, 2025, 7:17 PM EST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| Medical Countermeasures Products | 509.80M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Countermeasures Products Growth | 14.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Commercial Products | 398.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Commercial Products Growth | -19.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Services | 104.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Services Growth | 33.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconciling Items | 30.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reconciling Items Growth | 14.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Government - Medical Countermeasures and Commercial Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing Services | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing Services Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nasal Naloxone Products | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Nasal Naloxone Products Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing - Services | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Contract Development and Manufacturing - Leases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Anthrax Vaccines | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Anthrax Vaccines Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ACAM2000 | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ACAM2000 Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
| Other | 80.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -63.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 822.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 35.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Canada | 140.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Canada Growth | -37.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 80.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -63.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|